Corynebacterium pseudodiphtheriticum: Structure, Genetics, and Virulence

Corynebacterium pseudodiphtheriticum is a Gram-positive, non-toxigenic bacterium that lives harmlessly in the upper respiratory tract and on the skin of most healthy people, yet it can shift into an opportunistic pathogen when the host’s defenses falter. Its name hints at a resemblance to the diphtheria-causing Corynebacterium diphtheriae, but it lacks the infamous diphtheria toxin gene. That absence shapes almost everything interesting about the organism: its genetics, the way it interacts with human tissue, and the growing scientific interest in whether it could actually be harnessed to protect us from more dangerous microbes.

Cell Structure and Where It Fits in the Family Tree

Like other corynebacteria, C. pseudodiphtheriticum is a club-shaped, non-motile rod. Under the microscope, the cells often arrange themselves in irregular clusters or at angles to one another, a pattern sometimes called “Chinese letters” or “picket fence” arrangement. The cell wall follows the architecture typical of actinobacteria: a thick peptidoglycan layer studded with short-chain mycolic acids. These mycolic acids are much shorter than those found in mycobacteria (the genus responsible for tuberculosis and leprosy), but they still contribute to the waxy, hydrophobic quality of the cell surface, which turns out to be relevant for how the bacterium sticks to surfaces and forms biofilms.

Phylogenetic analyses based on 16S rRNA gene sequences place C. pseudodiphtheriticum firmly within the genus Corynebacterium, which itself belongs to a natural suprageneric group of mycolic acid-containing taxa that includes Mycobacterium, Rhodococcus, Nocardia, and several other genera.¹ Within that tree, C. pseudodiphtheriticum clusters close to C. diphtheriae but diverges in key genetic content, most critically the absence of the tox gene that encodes diphtheria toxin. The species is catalase-positive, oxidase-negative, non-lipophilic, and does not ferment most sugars, traits that historically helped microbiologists distinguish it from its more dangerous relative.

Genomics and Metabolic Wiring

Whole-genome studies of nasal-associated Corynebacterium species, including C. pseudodiphtheriticum, reveal a relatively compact genome and a pangenomic structure that is broadly similar across nasal corynebacteria.² Gene clusters for core metabolic functions are overwhelmingly concentrated in the “persistent” genome, meaning they show up in nearly every strain, not just a few. That pattern tells us something practical: different strains of C. pseudodiphtheriticum living side by side in the same person’s nose have limited ability to carve out distinct metabolic niches, because their metabolic toolkits are almost identical.

One striking exception emerged in geographic comparisons. Strains from a U.S. clade of C. pseudodiphtheriticum were found to lack the genes for assimilatory sulfate reduction that are present in most strains from a Botswana clade and in other nasal Corynebacterium species.² Assimilatory sulfate reduction is the pathway by which bacteria convert inorganic sulfate into the sulfur-containing amino acids they need to build proteins. Losing those genes means the U.S. strains presumably depend on their host or on neighboring microbes for preformed sulfur compounds. This kind of geographically linked gene loss is a snapshot of ongoing evolution, and it raises questions about whether metabolic streamlining affects the organism’s behavior as a commensal or a pathogen.

What Makes It Stick and How It Builds Biofilms

One of the most clinically relevant features of C. pseudodiphtheriticum is its ability to form biofilms, the structured microbial communities that cling to surfaces and resist both immune clearance and antibiotics. Laboratory work with strains isolated from patients with pharyngitis and bacteremia showed that C. pseudodiphtheriticum adheres to both hydrophilic and hydrophobic surfaces. On hydrophobic polystyrene, adhesion appears to be driven by the hydrophobic character of the cell surface itself, which fits with the waxy mycolic acids in the cell wall.³

Once attached, the bacteria multiply into microcolonies held together by intercellular adhesion molecules and an extracellular matrix. Over time, these microcolonies mature into dense bacterial aggregates embedded in a slimy exopolymeric matrix, with fluid-filled channels running through them, exactly the architecture seen in clinically significant biofilms of other species. The same study found that C. pseudodiphtheriticum also recognizes and binds human fibrinogen and fibronectin, two proteins abundant in blood and on tissue surfaces. These host proteins can form “conditioning films” on implanted medical devices or damaged tissue, giving the bacterium a foothold for colonization in vivo.³ The ability to bind these serum components is part of what enables C. pseudodiphtheriticum to transition from harmless commensal to invasive pathogen.

Virulence Factors Without the Toxin

Because C. pseudodiphtheriticum does not carry the tox gene, it cannot produce diphtheria toxin. That single genetic absence separates it from the most feared member of the genus. But lacking the headline toxin does not mean it lacks virulence tools. Across the Corynebacterium genus, key virulence concepts include the Pld protein (a phospholipase D) and the sortase-mediated mechanism for anchoring surface proteins to the cell wall.⁴ Sortases are enzymes that covalently attach proteins bearing a specific signal to the peptidoglycan layer, essentially bolting adhesins and other surface factors onto the outside of the cell. For C. pseudodiphtheriticum, this machinery helps display the adhesins that mediate binding to host tissue and the formation of biofilms described above.

The various adhesins that C. pseudodiphtheriticum expresses remain under active investigation, but the biofilm and binding data suggest a repertoire of surface-associated proteins that recognize host extracellular matrix components. The organism also appears to produce lipase activity that, as we will see, plays a surprising role not in attacking the host but in competing with other bacteria.

A Commensal That Fights Off Pathogens

Perhaps the most fascinating aspect of C. pseudodiphtheriticum biology is its protective behavior within the airway microbiome. The bacterium is commonly found in the nasopharynx of healthy children, often alongside Dolosigranulum pigrum, and the presence of both species has been associated with respiratory health rather than disease.⁵ When these two commensals were tested together against Streptococcus pneumoniae, they synergistically inhibited pneumococcal growth, suggesting a cooperative defense strategy in the nasal ecosystem.

Mouse experiments have made the protective picture even clearer. Pre-exposing the airways to C. pseudodiphtheriticum reduced the ability of both Staphylococcus aureus and S. pneumoniae to infect the lungs.⁶ The mechanisms are not one-size-fits-all. Against S. pneumoniae, Corynebacterium lipase activity was directly bactericidal, essentially dissolving the pathogen’s membrane. Against S. aureus, lipase was ineffective, but C. pseudodiphtheriticum secreted a protease factor that blocked the hemolytic activity of S. aureus pore-forming toxins. In both cases, live Corynebacterium needed to be colonizing the epithelial cells for the protective effect to hold; heat-killed bacteria or filtered supernatant alone did not replicate the full benefit.

A separate line of research found that C. pseudodiphtheriticum can even kill S. aureus, including methicillin-resistant strains (MRSA), through a contact-independent mechanism. The killing required the S. aureus Agr quorum-sensing system to be functional: when the gene for the Agr sensor kinase was knocked out in S. aureus, the bacteria became resistant to C. pseudodiphtheriticum-mediated killing.⁷ In other words, C. pseudodiphtheriticum turns S. aureus’s own virulence machinery against it, a clever exploitation that researchers have described as a novel polymicrobial defense strategy.

When the Commensal Turns Pathogen

Despite all this protective potential, C. pseudodiphtheriticum is not always benign. Over four decades of case reports have documented it as an agent of both community-acquired and hospital-acquired infections, with cases appearing across many countries.⁸ Respiratory infections are the most common clinical presentation. In one case series, roughly two-thirds of reported infections were upper respiratory, including rhinosinusitis, tracheitis, and bronchitis, while about a fifth were pneumonia.⁹

In a study of lower respiratory tract specimens, clinical relevance was judged likely or possible in the majority of patients from whom the organism was recovered, and pre-existing comorbidities, mostly heart or lung disease, were present in a similarly high proportion.¹⁰ The pattern is clear: the bacterium rarely causes disease in otherwise healthy people, but in patients whose local or systemic defenses are compromised, it can seize the opportunity. Intubation, mechanical ventilation, chronic lung disease, and immunosuppression are recurring risk factors in the case literature.

Beyond the lungs, C. pseudodiphtheriticum has been associated with endocarditis, a serious infection of the heart valves. In a large review of Corynebacterium endocarditis cases, C. pseudodiphtheriticum accounted for about 14% of all cases, second only to non-toxigenic C. diphtheriae.¹¹ A separate review of five endocarditis cases caused by C. pseudodiphtheriticum described two deaths, two patients with prosthetic valve infections who required both antibiotics and valve replacement surgery, and one patient with native valve infection who was cured with penicillin alone.¹² Prosthetic heart valves are a particular concern, likely because the biofilm-forming ability and fibrinogen-binding properties of C. pseudodiphtheriticum give it an advantage on artificial surfaces coated with host proteins.

How the Immune System Responds

Even though C. pseudodiphtheriticum normally coexists peacefully with its host, the immune system does not ignore it. Human corneal epithelial cells exposed to C. pseudodiphtheriticum showed elevated expression of Toll-like receptors (the pattern-recognition molecules that detect microbial components), along with increases in the inflammatory cytokines IL-6 and IL-1β. The cells also activated NF-κB and MAPK signaling pathways and ramped up production of antimicrobial peptides including S100A8, S100A9, and human β-defensin 1.¹³ These antimicrobial peptides help control microbial populations on mucosal surfaces, so the fact that a commensal triggers their release may actually be part of why the bacterium helps keep more dangerous organisms in check.

In the respiratory tract, macrophages efficiently engulf C. pseudodiphtheriticum, and the encounter triggers production of multiple pro-inflammatory cytokines, including TNF-α, IFN-γ, IL-6, and IL-1β.¹⁴ This immunostimulatory profile is modest enough to avoid tissue damage in a healthy person but potent enough to prime local defenses, which is exactly why researchers have become interested in whether C. pseudodiphtheriticum could be used as a mucosal adjuvant, a substance that enhances the immune response to vaccines delivered through the nose.

Antimicrobial Resistance Patterns

When C. pseudodiphtheriticum does cause an infection that requires treatment, the antibiotic landscape is mostly favorable but carries some important caveats. One clinical study found all isolates susceptible to amoxicillin, which aligns with older literature showing reliable activity of beta-lactam antibiotics.¹⁰ However, macrolide resistance is widespread. A study of upper respiratory tract isolates found that the vast majority, nearly 90%, displayed constitutive resistance to macrolides, lincosamides, and streptogramin B antibiotics, mediated by the erm(X) gene.¹⁵ This matters because macrolides like erythromycin and azithromycin are commonly prescribed empirically for respiratory infections. If C. pseudodiphtheriticum is the culprit, macrolides are likely to fail.

More concerning, some isolates show multidrug resistance. Susceptibility testing from another study reported universal resistance to erythromycin and tetracycline, with some isolates also resistant to penicillin, and resistance profiles extending to as many as seven different antibiotic classes including vancomycin, gentamicin, and linezolid.¹⁶ All isolates in that study remained sensitive to ciprofloxacin and ceftriaxone. The erm(X) gene sits on mobile genetic elements, raising the possibility that C. pseudodiphtheriticum could share macrolide resistance with other Corynebacterium species that colonize the same mucosal surfaces.¹⁵ So even when this organism is not causing disease itself, it may serve as a reservoir of resistance genes in the nasal microbiome.

Getting the Identification Right

One practical challenge with C. pseudodiphtheriticum is making sure it is identified correctly in the clinical laboratory. Historically, Corynebacterium species other than C. diphtheriae were often dismissed as contaminants or grouped loosely as “diphtheroids,” which meant clinically significant infections were underreported. Modern identification methods have improved matters considerably. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) correctly identified the vast majority of non-diphtheriae Corynebacterium isolates to the species level in a study evaluating 92 clinical isolates, with only one misidentification involving a closely related species pair.¹⁷ Molecular sequencing of the rpoB or 16S rRNA genes serves as a reference standard when mass spectrometry results are ambiguous. The broader availability of these tools in clinical labs has contributed to the rise in reported C. pseudodiphtheriticum infections over the past two decades: more accurate identification, more recognized cases.

Probiotic and Vaccine Adjuvant Research

The protective effects observed in animal models have driven a small but growing body of research into therapeutic applications. One experimental strain, C. pseudodiphtheriticum 01-1, was used as a nasal probiotic in malnourished mice and improved their resistance to respiratory syncytial virus and secondary pneumococcal infections.¹⁸ Malnourished hosts are particularly relevant because malnutrition weakens mucosal immunity and is a leading risk factor for childhood respiratory death in low-income settings. If a nasal probiotic could partially restore local immune tone, the impact could be substantial.

Separately, the immunostimulatory profile of C. pseudodiphtheriticum has attracted attention for vaccine adjuvant development. Because the bacterium and its bacterial-like particles are efficiently taken up by respiratory macrophages and trigger a cocktail of cytokines, they could serve as mucosal adjuvants that boost the immune response to nasally administered vaccines.¹⁴ Most current injectable vaccines generate strong systemic immunity but weaker mucosal immunity, which is the front line for respiratory pathogens. Adding C. pseudodiphtheriticum-derived components to nasal vaccine formulations could, in theory, improve protection at the site where pathogens first land. These applications remain in preclinical stages, and the dual nature of the organism, protective commensal in healthy hosts, opportunistic pathogen in vulnerable ones, means safety thresholds for any therapeutic use would need to be carefully defined.

Nosocomial Outbreaks and Emerging Concern

Hospital-acquired C. pseudodiphtheriticum infections have been documented in multiple countries over the past four decades, ranging from isolated cases to small outbreaks on intensive care units and cardiothoracic surgery wards.⁸ The combination of biofilm formation on ventilator tubing and prosthetic devices, widespread macrolide resistance, and the tendency for clinical labs to dismiss corynebacteria as irrelevant contaminants has created a blind spot in infection control. Patients who are intubated, immunosuppressed, or recovering from cardiac surgery are the most vulnerable.

As identification technology becomes more routine in hospitals, the case count will likely continue to rise. Whether that reflects a genuine increase in pathogenicity or simply better recognition of an organism that has always caused sporadic infections remains an open question. Either way, the organism occupies an unusual position in clinical microbiology: a bacterium that most of the time helps defend the airway, but that clinicians in certain settings need to take seriously as a cause of pneumonia, endocarditis, and occasionally bloodstream infection.